Zometa

Zoledronic Acid Therapy Impacts Risk and Frequency of Skeletal Complications In Men with Prostate Cancer – Start Early Therapy

To evaluate the effects of timing and length of zoledronic acid (ZA) treatment on outcomes for men with prostate cancer, researchers from the University of Illinois at Chicago and the Hind T. Hatoum & Company, Chicago, IL. evaluated a large contingent of men who had been diagnosed with prostate cancer from January 2003 to October [...]

By |2010-12-28T11:32:31-05:00December 28th, 2010|Advanced Prostate Cancer, bisphosphonates, Drugs & Treatments, General Information, Metastases, Research, Uncategorized, Understanding APC, Zometa|1 Comment
Read More

Zoledronic Acid Shows Improved Clinical Outcomes When Administered Prior to Bone Pain in Men with Advanced Prostate Cancer

According to the FDA approval label, zoledronic acid (Zometa) should be administered to men with advanced prostate cancer once they have failed one hormone therapy type, in other words, once the cancer has become castrate resistant. Researchers at the Centre Hospitalier de i’Université de Montréal, Hôpital Notre-Dame, Montréal, Quebec, Canada evaluated the effect of zoledronic [...]

By |2017-10-19T10:53:24-04:00December 15th, 2010|Advanced Prostate Cancer, bisphosphonates, Drugs & Treatments, General Information, Metastases, Uncategorized, Understanding APC, Zometa|2 Comments
Read More
Go to Top